Compare IPSC & MTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | MTRX |
|---|---|---|
| Founded | 2019 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 275.6M |
| IPO Year | 2021 | 1995 |
| Metric | IPSC | MTRX |
|---|---|---|
| Price | $1.61 | $10.46 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | 386.4K | ★ 425.2K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.30 | ★ 91.51 |
| EPS | N/A | ★ N/A |
| Revenue | $109,164,000.00 | ★ $873,632,000.00 |
| Revenue This Year | N/A | $6.70 |
| Revenue Next Year | N/A | $5.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1556.76 | 13.56 |
| 52 Week Low | $0.44 | $9.39 |
| 52 Week High | $2.97 | $15.97 |
| Indicator | IPSC | MTRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 34.04 |
| Support Level | $0.90 | N/A |
| Resistance Level | $2.39 | $14.18 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 11.36 | 21.83 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Matrix Service Co provides engineering, fabrication, construction, and maintenance services supporting critical energy infrastructure and industrial markets. Its reportable segments are Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities, with Storage and Terminal Solutions generating the maximum revenue. This segment provides integrated EPC, repair, maintenance, and fabrication services for bulk liquid, cryogenic, and refrigerated storage and terminal facilities supporting traditional and emerging energy markets, including LNG, NGLs, petroleum products, chemicals, hydrogen, and ammonia, and manufactures specialty tank products. The majority of revenue is generated from the United States.